Carnitine metabolism in hypertensive heart failure.

CommentOn

Hypertens Res. 2025 Mar;48(3):1109-1114. doi: 10.1038/s41440-025-02106-1.

COI Statement

Compliance with ethical standards. Conflict of interest: The authors declare no competing interests.

References:

• Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac energy metabolism in heart failure. Circ Res. 2021;128:1487–513.
• Harada H, Nishiyama Y, Katoh A, Niiyama H, Iwaki A, Ohchi Y, et al. Heart failure treatment and serum carnitines in HFpEF and HFrEF with or without hypertension - A pilot study. Hypertens Res. 2025. https://doi.org/10.1038/s41440-025-02106-1 .
• Reuter SE, Evans AM. Carnitine and Acylcarnitines: Pharmacokinetic, pharmacological and clinical aspects. Clin Pharmacokinet. 2012;51:553–72.
• Ueland T, Svardal A, Oie E, Askevold ET, Nymoen SH, Bjorndal B, et al. Disturbed carnitine regulation in chronic heart failure-increased plasma levels of palmitoyl‐carnitine are associated with poor prognosis. Int J Cardiol. 2013;167:1892–9.
• Yoshihisa A, Watanabe S, Yokokawa T, Misaka T, Sato T, Suzuki S, et al. Associations between acylcarnitine to free carnitine ratio and adverse prognosis in heart failure patients with reduced or preserved ejection fraction. ESC Heart Fail. 2017;4:360–4.